Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis (Q28069975)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis	scientific article

Statements

scholarly article

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2 references

Europe PubMed Central

6 August 2020

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis (English)

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

5 references

24 March 2019

17 November 2019

20 November 2019

19 December 2019

6 August 2020

1 reference

17 November 2019

1 reference

20 November 2019

nerve tissue proteins

1 reference

19 December 2019

Natriuretic peptide, brain type

1 reference

6 August 2020

1 reference

based on heuristic

inferred from title

Angela Dispenzieri

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Giovanni Palladini

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

5

object named as

M A Gertz

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

G Merlini

1

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

I Lousada

2

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

M Grogan

6

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

M S Maurer

7

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

V Sanchorawala

8

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

A Wechalekar

9

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

R L Comenzo

11

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Yukio Ando

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

1 reference

publication date

15 July 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 October 2016

1 reference

6 August 2020

7 references

24 March 2019

17 November 2019

20 November 2019

19 December 2019

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

6 August 2020

30

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1979-1986

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

10

2 references

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

copyright license

Creative Commons Attribution 4.0 International

5 references

Europe PubMed Central

24 March 2019

Europe PubMed Central

17 November 2019

Europe PubMed Central

20 November 2019

Europe PubMed Central

19 December 2019

Europe PubMed Central

6 August 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

20 March 2017

Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

20 March 2017

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Novel strategies for the diagnosis and treatment of cardiac amyloidosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Cardiovascular magnetic resonance for amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

State of the art of immunoassay methods for B-type natriuretic peptides: An update.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

T1 mapping and survival in systemic light-chain amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Pathophysiology and treatment of cardiac amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Immunoglobulin light chain amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Cardiac amyloidosis: updates in diagnosis and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Systemic amyloidosis in England: an epidemiological study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Biomarkers and diagnostics in heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

What do I need to know about immunoglobulin light chain (AL) amyloidosis?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Emerging biomarkers in heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Amyloidosis: pathogenesis and new therapeutic options.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Clinical aspects of systemic amyloid diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

29 September 2017

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

2 June 2018

How to image cardiac amyloidosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

2 June 2018

Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5056962

2 June 2018

Systemic light chain amyloidosis: an update for treating physicians

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Light chain amyloidosis: the heart of the problem

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

B-type natriuretic peptide -- a window to the heart.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Mechanical strain increases expression of the brain natriuretic peptide gene in rat cardiac myocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Distinct regulation of B-type natriuretic peptide transcription by p38 MAPK isoforms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2016.191

21 January 2018

Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiac amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines on the management of AL amyloidosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27416985

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2016.191

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27416985%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Springer Nature article ID

10.1038/leu.2016.191

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28069975&oldid=1962483180"